- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06099418
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.
A Two-Arm Randomized, Double-Blind, Placebo-Controlled Phase 2 Selection Trial to Evaluate the Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With HPV16-Positive, PD-L1-positive, Recurrent or Metastatic Cervical Cancer Who Are Refractory to Pembrolizumab With Chemotherapy With/Without Bevacizumab.
This is a multi-center study in patients with recurrent or metastatic HPV16-positive, PD-L1 positive cervical cancer who has progressed during or after treatment with the first-line standard of care (pembrolizumab with chemotherapy with/without bevacizumab).
The trial is designed to investigate VB10.16 alone or in combination with the immune checkpoint inhibitor, atezolizumab.
The trial consist of 2 parts: the first part which investigates VB10.16 + placebo versus VB10.16 + atezolizumab. Approximately 30 patients will be included in each group. The goal of this part is to evaluate which of the two treatments is the best.
The second part of the study will select the best treatment from part 1 and investigate the safety and efficacy of additional 70 patients.
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a two-arm randomized, double-blind, placebo-controlled phase 2 selection trial to evaluate the efficacy and safety of VB10.16 alone or in combination with atezolizumab in patients with HPV16-positive, PD-L1-positive, recurrent or metastatic cervical cancer who are refractory to pembrolizumab with chemotherapy with/without bevacizumab. A selection design with a margin of practical equivalence will be implemented to monitor efficacy of the two experimental arms (VB10.16 + atezolizumab vs. VB10.16 + placebo).
The trial consist of 2 parts: the first part which investigates VB10.16 + placebo versus VB10.16 + atezolizumab. Approximately 30 patients will be included in each group. The goal of this part is to evaluate which of the two treatments is the superior.
The second part of the study will select the superior treatment from part 1 and investigate the safety and efficacy of additional 70 patients.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Medical Lead Officer
- Phone Number: +45 61303308
- Email: roliveri@nykode.com
Study Contact Backup
- Name: Senior Clinical Trial Manager
- Phone Number: +47 909 975 95
- Email: hwold@nykode.com
Study Locations
-
-
Alabama
-
Mobile, Alabama, United States, 36604
- Not yet recruiting
- Mitchell Cancer Institute
-
Contact:
- Jennifer Pierce, MD
-
-
Colorado
-
Denver, Colorado, United States, 80045
- Not yet recruiting
- University of Colorado Cancer Center
-
Contact:
- Jill Alldrige, MD
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Not yet recruiting
- University of Iowa
-
Contact:
- David Bender, MD
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28402
- Not yet recruiting
- Atrium Health Levine Cancer Institute
-
Contact:
- Erin Crane, MD, MPH
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic
-
Contact:
- Peter G Rose, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Age ≥18 years at ICF signature date.
Persistent recurrent or metastatic (R/M) (stage IVB) PD-L1 positive cervical cancer with squamous cell, adenocarcinoma or adenosquamous histology with confirmed disease progression during or after treatment with 1st line systemic standard of care pembrolizumab + platinum-containing chemotherapy +/- bevacizumab
- Participants should have received at least 4 cycles of pembrolizumab.
- Planned treatment start should be within 12 weeks of documented radiographic disease progression.
- Participants should have received no more than 1 prior systemic anti-cancer treatment regimen for recurrent/metastatic cervical cancer (pembrolizumab + chemotherapy +/- bevacizumab).
- PD-L1-positive tumor confirmed by Ventana SP263 clone (the Food and Drug Administration approved companion diagnostic test for atezolizumab in other indications), with tumor area positivity ≥5% in designated central laboratory
- HPV16-positive tumor confirmed by nucleic acid amplification test in designated central laboratory
At least 1 measurable lesion per RECIST v1.1 as assessed by Blinded Independent Central Review.
Overall function and organ function:
- ECOG performance status (PS) ≤1
- Gustave Roussy Immune (GRIm) score ≤1
Key Exclusion Criteria:
Disease specific:
- Has disease that is suitable for local therapy with curative intent.
- Rapidly progressing disease (e.g., tumor bleeding, uncontrolled tumor pain) in the opinion of the investigator.
Neuroendocrine carcinoma of the cervix.
Prior, concurrent or future interventions:
- Radiotherapy (or other non-systemic therapy) ≤14 days prior to VB10.16 treatment start, or the patient has not fully recovered (i.e., Grade ≤1 at baseline) from AEs due to a previously administered treatment.
- Has received prior surgery or prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment.
- Prior solid organ or tissue transplantation (except corneal transplant).
- Prior autologous or allogeneic hematopoietic stem cell transplantation.
- Prior chimeric antigen receptor T-cell (CAR-T) therapy.
- Prior therapy with a monoclonal antibody, bispecific antibody, or antibody fragment (or other molecule with similar mechanism of action) that engages with stimulatory or co-inhibitory molecules on T cells (e.g., CD3, CTLA-4, PD-1, 4-1BB/CD137), except pembrolizumab in the metastatic setting.
- Prior therapy with CPI in the locally advanced setting.
- Prior administration with tisotumab vedotin.
- Administration of a live (attenuated replicating organism) or non-live (pathogen component or killed whole organism) vaccine, or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine within 30 days prior to VB10.16 treatment start.
- Prior administration with a therapeutic HPV16 vaccine.
- Prior severe hypersensitivity (≥ grade 3) to atezolizumab and/or any of its excipients.
- Prior persistent toxicities (≥ grade 3) related to pembrolizumab administration.
- Participants receiving systemic immunosuppression with immunosuppressive agents such as cyclosporine, azathioprine, methotrexate, or tumor necrosis factor alpha blockers for any concurrent condition.
- Chronic administration of systemic corticosteroids: prednisone >10 mg daily (or dose equivalent) or an average cumulative dose of >140 mg prednisone (or dose equivalent) within the last 14 consecutive days prior to VB10.16 treatment start.
Any planned major surgery.
Prior or concurrent morbidity:
Malignancy:
Past or current malignancy other than inclusion diagnosis, except for:
- Noninvasive basal cell or squamous cell skin carcinoma.
- Noninvasive, superficial bladder cancer.
- Ductal carcinoma in situ.
- Any curable cancer with a complete response of >2 years' duration.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: VB10.16 + placebo
9 mg VB10.16 via i.m. needle free injections in the deltoid muscles and quadricep or gluteus muscle. Placebo will be given via IV infusions. |
Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 49. A total of up to 11 i.m. administrations will be given. VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system.
Intravenous (IV) infusions of placebo (saline solution) every 3 weeks.
|
Experimental: VB10.16 + atezolizumab
9 mg VB10.16 via i.m. needle free injections in the deltoid muscles and quadricep or gluteus muscle. Atezolizumab will be given via IV infusions. |
Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 49. A total of up to 11 i.m. administrations will be given. VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system.
Intravenous (IV) infusions of atezolizumab (saline solution) every 3 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Up to 1 year
|
Objective Response Rate (ORR), defined as the proportion of patients who have either confirmed CR or confirmed PR as best overall response per RECIST 1.1 as assessed by blinded independent central review (BICR).
|
Up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Up to approximately 2 year
|
Objective Response Rate (ORR), defined as the proportion of patients who have either confirmed CR or confirmed PR as best overall response per RECIST 1.1 as assessed by the investigator.
|
Up to approximately 2 year
|
Duration of Response (DOR)
Time Frame: Up to approximately 2 years
|
Duration of response (DOR) based upon RECIST v1.1 assessed by BICR.
DOR is defined as time from the date of first documented response of confirmed CR or PR to the date of the first documented progression or death due to any cause, whichever occur first.
|
Up to approximately 2 years
|
Duration of Response (DOR)
Time Frame: Up to approximately 2 years
|
Duration of response (DOR) based upon RECIST v1.1 assessed by the investigator.
DOR is defined as time from the date of first documented response of confirmed CR or PR to the date of the first documented progression or death due to any cause, whichever occur first.
|
Up to approximately 2 years
|
Time to Response (TTR)
Time Frame: Up to approximately 2 years
|
Time to response (TTR) based upon RECIST v1.1 assessed by BICR.
TTR is defined as the time from VB10.16 treatment start date to the date of first documented response of either confirmed CR or confirmed PR.
|
Up to approximately 2 years
|
Disease Control Rate (DCR)
Time Frame: Up to approximately 2 years
|
Disease Control Rate (DCR) based upon RECIST v1.1 assessed by BICR.
DCR is defined as the proportion of patients who have either confirmed CR, confirmed PR, or SD as best overall response.
|
Up to approximately 2 years
|
Duration of Disease Control (DODC)
Time Frame: Up to approximately 2 years
|
Duration of disease control (DODC) based upon RECIST v1.1 assessed by BICR.
DODC is defined as time from the date of first documented response of confirmed CR, confirmed PR or SD to the date of the first documented progression or death due to any cause.
|
Up to approximately 2 years
|
Progression Free Survival (PFS)
Time Frame: Up to approximately 2 years
|
Progression-free survival (PFS) as assessed by BICR.
PFS is defined as the time from the VB10.16 treatment start date to the date of the first documented progression or death from any cause, whichever occurs first.
|
Up to approximately 2 years
|
Progression Free Survival (PFS)
Time Frame: Up to approximately 2 years
|
Progression-free survival (PFS) as assessed by the investigator.
PFS is defined as the time from the VB10.16 treatment start date to the date of the first documented progression or death from any cause, whichever occurs first.
|
Up to approximately 2 years
|
Overall survival (OS)
Time Frame: Up to approximately 2 years
|
Overall survival (OS), defined as the time from VB10.16 treatment start date to the date of death from any cause.
|
Up to approximately 2 years
|
Minimal Response
Time Frame: Up to approximately 2 years
|
Proportion of participants with tumor shrinkage ≥10.0% to <30% assessed by BICR.
|
Up to approximately 2 years
|
Proportion of participants who are Progression-free
Time Frame: 26 weeks
|
Proportion of participants who are progression-free and alive based upon RECIST v1.1 assessed by BICR.
|
26 weeks
|
Proportion of participants who are Progression-free
Time Frame: 52 weeks
|
Proportion of participants who are progression-free and alive based upon RECIST v1.1 assessed by BICR.
|
52 weeks
|
Proportion of participants who are Progression-free
Time Frame: 104 weeks
|
Proportion of participants who are progression-free and alive based upon RECIST v1.1 assessed by BICR.
|
104 weeks
|
Proportion of participants who are alive.
Time Frame: 26 weeks
|
Proportion of participants who are alive.
|
26 weeks
|
Proportion of participants who are alive.
Time Frame: 52 weeks
|
Proportion of participants who are alive.
|
52 weeks
|
Proportion of participants who are alive.
Time Frame: 104 weeks
|
Proportion of participants who are alive.
|
104 weeks
|
Molecular Response
Time Frame: Up to week 52
|
Proportion of participants with molecular response defined as ≥30% decrease from baseline in HPV16 ctDNA.
|
Up to week 52
|
Molecular Response
Time Frame: Up to week 52
|
Proportion of participants with molecular response defined as ≥50% decrease from baseline in HPV16 ctDNA.
|
Up to week 52
|
Proportion of participants with treatment emergent adverse events
Time Frame: Up to week 104
|
Proportion of participants with treatment-emergent adverse events (TEAEs) by severity grade.
|
Up to week 104
|
Proportion of participants with treatment-emergent serious adverse events
Time Frame: Up to week 104
|
Proportion of participants with treatment-emergent serious adverse events
|
Up to week 104
|
Proportion of participants with drug related toxicity
Time Frame: Up to week 104
|
Proportion of participants with drug-related toxicity of CTCAE grade ≥3
|
Up to week 104
|
Proportion of participants with discontinuation
Time Frame: Up to week 104
|
Proportion of participants discontinuing treatment due to an adverse reaction.
|
Up to week 104
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ritu Salani, MD MBA, UCLA Division of Gynecologic Oncology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Uterine Cervical Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Atezolizumab
Other Study ID Numbers
- VB-C-04
- GOG-3091 (Other Identifier: GOG Foundation)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Cancer
-
University of California, San DiegoWithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III | Cervical Cancer Stage IIIB | Cervical Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterWithdrawnStage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage III Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO... and other conditions
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnCervical Cancer | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IA Cervical Cancer | Stage IB Cervical Cancer | Stage IA1 Cervical Cancer | Stage IA2 Cervical Cancer | Stage IB1 Cervical Cancer | Stage IB2 Cervical Cancer | Stage IB3 Cervical CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingCervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical... and other conditionsUnited States
-
Shanghai First Maternity and Infant HospitalNot yet recruitingCervical Cancer, Stage IIB | Cervical Cancer Stage IIIB | Cervical Cancer Stage IIIA | Cervical Cancer, Stage IVA
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical Cancer | Stage IIIA Cervical Cancer | Stage IIIB Cervical CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical CancerUnited States
-
Institut de Cancérologie de LorraineCompletedCervical Adenocarcinoma | Stage IB Cervical Cancer | Stage III Cervical Cancer | Stage II Cervical CancerFrance
Clinical Trials on VB10.16
-
Nykode Therapeutics ASARoche Pharma AG; Vaccibody ASCompletedCervical Cancer | Cervix CancerBelgium, Germany, Bulgaria, Czechia, Norway, Poland
-
Nykode Therapeutics ASATheradex; Vaccibody ASCompletedHigh Grade Cervical Intraepithelial NeoplasiaGermany
-
Nykode Therapeutics ASAMerck Sharp & Dohme LLCRecruitingHNSCC | HPV-Related Squamous Cell CarcinomaFrance, Norway, Spain, United Kingdom, Hungary, Poland, Czechia, Germany